Success Metrics

Active Trials
4(100%)

Phase Distribution

Ph phase_1
4
100%

Phase Distribution

4

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
4(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

4

all time

Status Distribution
Active(4)

Detailed Status

Recruiting4

Development Timeline

Analytics

Development Status

Total Trials
4
Active
4
Success Rate
N/A
Most Advanced
Phase 1

Trials by Phase

Phase 14 (100.0%)

Trials by Status

recruiting4100%

Recent Activity

4 active trials
Showing 4 of 4
recruitingphase_1

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

NCT06922591
recruitingphase_1

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

NCT06445062
recruitingphase_1

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

NCT06162221
recruitingphase_1

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

NCT06040541

Clinical Trials (4)

Showing 4 of 4 trials
NCT06922591Phase 1

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

Recruiting
NCT06445062Phase 1

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Recruiting
NCT06162221Phase 1

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

Recruiting
NCT06040541Phase 1

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

Recruiting

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4